Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)

OBJECTIVE: To evaluate the sustained remission and low disease activity after discontinuation of tocilizumab in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate. METHODS: The SURPRISE study was a 2-year, open-label randomised controlled s...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaneko, Yuko, Kato, Masaru, Tanaka, Yoshiya, Inoo, Masayuki, Kobayashi-Haraoka, Hitomi, Amano, Koichi, Miyata, Masayuki, Murakawa, Yohko, Yasuoka, Hidekara, Hirata, Shintaro, Tanaka, Eiichi, Miyasaka, Nobuyuki, Yamanaka, Hisashi, Yamamoto, Kazuhiko, Takeuchi, Tsutomu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104678/
https://www.ncbi.nlm.nih.gov/pubmed/29853455
http://dx.doi.org/10.1136/annrheumdis-2018-213416

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104678/
https://www.ncbi.nlm.nih.gov/pubmed/29853455
http://dx.doi.org/10.1136/annrheumdis-2018-213416

Ejemplares similares